score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical evidence	Rearrangement	TMPRSS2	Fusion	TMPRSS2--ERG			0.0	0.0		Putatively Actionable	Rucaparib	PARP inhibition	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408								Putatively Actionable	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ERG Fusion	0.0	SC_9060		
Putatively Actionable	Preclinical		Clinical evidence	Rearrangement	ERG	Fusion	TMPRSS2--ERG			0.0	0.0		Putatively Actionable	Rucaparib	PARP inhibition	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408								Putatively Actionable	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ERG Fusion	0.0	SC_9060		
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.273						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (27%)		SC_9060		
Investigate Actionability		Guideline	Clinical trial	Somatic Variant	TP53	Nonsense	p.W146*	0.2551	243.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	79.0	0.0759	1.0	TP53 p.W146* (Nonsense)		SC_9060	SC_9060-Tumor	SC_9060-Normal
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9060		
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Deletion	p.N114del	0.3664	232.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	PIK3CA p.N114del (Deletion)	1.0	SC_9060	SC_9060-Tumor	SC_9060-Normal
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.Q1088L	0.0333	120.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	89.0	0.0	0.4609	CDK12 p.Q1088L (Missense)	0.0	SC_9060	SC_9060-Tumor	SC_9060-Normal
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		SC_9060		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.296																									0				COSMIC Signature (version 2) 6 (30%)		SC_9060		
